A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many
patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity
and adversely affects the quality of life. In an earlier study, we have observed marked
improvement in RP attacks and rapid healing of digital ulcers following therapy with
phosphodiesterase V inhibitor, Tadalafil. In the present multicentric study we aim to study
the efficacy of Tadalafil in patients continuing to have RP attacks despite using at least
one or more vasodilators.
Phase:
Phase 3
Details
Lead Sponsor:
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Collaborators:
Army Research and Referral hospital Institute of Postgraduate Medical Education and Research Postgraduate Institute of Medical Education and Research